Exploring Three High Growth Tech Stocks In The United States

The United States market has shown robust performance recently, climbing 3.0% in the last week and achieving a 25% increase over the past year, with earnings expected to grow by 15% annually. In this favorable environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and scalability aligned with these positive market trends.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
Exelixis	61.26%	20.47%	★★★★★★
Super Micro Computer	24.36%	24.28%	★★★★★★
Ardelyx	21.46%	54.72%	★★★★★★
AsiaFIN Holdings	51.75%	82.69%	★★★★★★
AVITA Medical	33.20%	51.87%	★★★★★★
Alkami Technology	21.99%	102.65%	★★★★★★
TG Therapeutics	29.87%	43.91%	★★★★★★
Clene	61.16%	59.11%	★★★★★★
Alnylam Pharmaceuticals	21.39%	56.66%	★★★★★★
Travere Therapeutics	30.46%	62.13%	★★★★★★

Click here to see the full list of 226 stocks from our US High Growth Tech and AI Stocks screener.

Let's review some notable picks from our screened stocks.

Alnylam Pharmaceuticals (NasdaqGS:ALNY)

Simply Wall St Growth Rating: ★★★★★★

Overview: Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapeutics using ribonucleic acid interference technology, with a market capitalization of $34.38 billion.

Operations: Alnylam focuses on the discovery, development, and commercialization of RNAi therapeutics, generating revenue primarily from this segment at $2.09 billion.

Alnylam Pharmaceuticals, demonstrating robust growth, forecasts a significant revenue increase to between $2.05 billion and $2.25 billion for 2025, marking an ambitious 31% rise from the previous year at the midpoint. This surge is propelled by its key franchises ONPATTRO and AMVUTTRA in the TTR segment, expected to generate up to $1.725 billion alone. Concurrently, Alnylam's commitment to innovation is underscored by a substantial R&D focus, with recent FDA advancements for vutrisiran indicating potential market expansion into ATTR amyloidosis treatment with cardiomyopathy—a move that could redefine therapeutic standards in this niche medical field.

• Dive into the specifics of Alnylam Pharmaceuticals here with our thorough health report.

• Explore historical data to track Alnylam Pharmaceuticals' performance over time in our Past section.

Vertex Pharmaceuticals (NasdaqGS:VRTX)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Vertex Pharmaceuticals Incorporated is a biotechnology company focused on developing and commercializing therapies for cystic fibrosis, with a market capitalization of approximately $110.22 billion.

Operations: Vertex Pharmaceuticals generates revenue primarily from its pharmaceuticals segment, which amounts to $10.63 billion. The company's focus is on developing and commercializing therapies for cystic fibrosis.

Vertex Pharmaceuticals' strategic moves underscore its potential in the high-growth tech sector, particularly with its recent FDA approval expanding TRIKAFTA® use and collaborations like the one with Zai Lab to commercialize povetacicept in Asia. With an 8.4% annual revenue growth and a significant 36.7% forecast in earnings growth, Vertex is actively enhancing its market position. The firm's R&D dedication is evident from substantial investments leading to innovations such as CASGEVY™, the first CRISPR/Cas9 gene-edited therapy approved for severe diseases, which continues to show transformative long-term benefits. This blend of regulatory success and pioneering treatments positions Vertex favorably within biotech's evolving landscape.

• Navigate through the intricacies of Vertex Pharmaceuticals with our comprehensive health report here.

• Learn about Vertex Pharmaceuticals' historical performance.

Coherent (NYSE:COHR)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Coherent Corp. is a global company that develops, manufactures, and markets engineered materials and optoelectronic components for industrial, communications, electronics, and instrumentation markets with a market cap of approximately $16.70 billion.

Operations: Coherent Corp. operates across three main revenue segments: Lasers ($1.41 billion), Materials ($1.51 billion), and Networking ($2.63 billion). The company focuses on engineered materials, optoelectronic components, and optical systems for diverse markets globally.

Coherent's recent product launches, including the CT-Series thermoelectric coolers and FACTOR Series of fiber-coupled diode pumps, underscore its strategic focus on enhancing thermal management and pump efficiency across various high-demand applications in life sciences and industrial markets. These innovations not only expand its product lineup but also improve performance metrics crucial for OEM integration and reliability. With revenue expected to grow by 11% annually and earnings projected to surge by 111.5%, Coherent is poised for profitability within three years, reflecting its robust R&D investment strategy aimed at capturing emerging market opportunities effectively.

• Unlock comprehensive insights into our analysis of Coherent stock in this health report.

• Evaluate Coherent's historical performance by accessing our past performance report.

Next Steps

• Dive into all 226 of the US High Growth Tech and AI Stocks we have identified here.
• Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
• Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com